866-997-4948(US-Canada Toll Free)

Parkinsons Disease-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 69 Pages

DelveInsights Parkinsons Disease-Market Insights, Epidemiology and Market Forecast-2025report provides an overview of Parkinsons disease (PD), epidemiology and market trend of the Parkinsons disease (PD) for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Parkinsons disease (PD) from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Parkinsons disease (PD) till 2025.The Report also covers market drivers, market barriers and unmet medical need.

Our report provides the diagnosed cases of Parkinsons disease (PD). Changes in diagnostic practice over time and increase in aging population will slowly increase the diagnosed cases of PD. According to DelveInsight, the prevalent population of Parkinsons disease (PD) is expected to reach up to XXX cases by the end of 2025 at a CAGR of 4.69% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

The market size is driven by several approved drugs that are being used for the treatment of Parkinsons disease such as Neupro (UCB Group of Companies), Xadago (Newron Pharmaceuticals S.p.A.) and Exelon (Novartis).

United States contributes the major share of Parkinsons disease (PD) market as compared to EU5 countries and Japan. The therapeutic market of PD in 7MM is expected to reach USD 4.91 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Parkinsons disease (PD) market.
Organize sales and marketing efforts by identifying the best opportunities for Parkinsons disease in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the Parkinsons disease market and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The report provides historical as well as forecasted epidemiology of Parkinsons disease in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
The Report also covers the detailed historical and forecasted Parkinsons disease market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.

1. Report Introduction
2. Parkinson Disease Market Overview at a Glance
3. Total Market Share Distribution of Parkinson Disease for 7 MM in 2016
4. Total Market Share Distribution of Parkinson Disease for 7 MM in 2025
5. Parkinson Disease
6. Overview
6.1. Symptoms
6.2. Pathophysiology
6.3. Staging
6.4. Diagnosis
7. Parkinsons disease (PD) Geography wise Diagnosed Cases
8. 7MM Diagnosed PD Cases in 2016
9. 7MM Diagnosed PD Cases in 2025
10. Epidemiology and Patient Population
11. Key Points
12. Epidemiology Forecast Overview
12.1. United States
12.2. Diagnosed Cases of Parkinson Disease in United States
12.3. Europe
12.4. Germany
12.5. Diagnosed Cases of Parkinson Disease in Germany
12.6. France
12.7. Diagnosed Cases of Parkinson Disease in France
12.8. United Kingdom
12.9. Diagnosed Cases of Parkinson Disease in United Kingdom
12.10. Spain
12.11. Diagnosed Cases of Parkinson Disease in Spain
12.12. Italy
12.13. Diagnosed Cases of Parkinson Disease in Italy
12.14. Japan
13. Diagnosed Cases of Parkinson Disease in Japan
14. Treatment Algorithm
15. Unmet Needs
16. Marketed Drugs
16.1.1. Top Marketed Drugs for Parkinson disease
16.1.2. Azilect: Teva Pharmaceutical Industries
16.1.3. Drug Description
16.1.4. Mechanism of Action
16.1.5. Regulatory Milestones
16.1.6. Advantages & Disadvantages
16.1.7. Safety and Efficacy of Azilect
16.1.8. Product Profile
16.1.9. Exelon/Exelon Patch: Novartis
16.1.10. Drug Description
16.1.11. Mechanism of Action
16.1.12. Regulatory Milestones
16.1.13. Advantages & Disadvantages
16.1.14. Safety and Efficacy of Exelon
16.1.15. Product Profile
16.1.16. Stalevo: Orion Corporation
16.1.17. Drug Description
16.1.18. Mechanism of Action
16.1.19. Regulatory Milestones
16.1.20. Advantages & Disadvantages
16.1.21. Safety and Efficacy of Stalevo
16.1.22. Product Profile
16.1.23. Comtan/Comtess: Orion Corporation
16.1.24. Drug Description
16.1.25. Mechanism of Action
16.1.26. Regulatory Milestones
16.1.27. Advantages & Disadvantages
16.1.28. Safety and Efficacy of Comtan/Comtess
16.1.29. Product Profile
17. Emerging Therapies
18. Major Pipeline drugs
18.1. Tozadenant
18.2. Advantages & Disadvantages
18.3. Product Profile
18.4. Clinical Development
18.5. Clinical Pipeline Activity
18.6. Ongoing Trials Information
18.7. Clinical Trial by Phase
18.8. CVT-301
18.9. Product Profile
18.10. Clinical Development
18.11. Clinical Pipeline Activity
18.12. Ongoing Trials Information
18.13. Clinical Trial by Phase
18.14. Gene Therapy: Future possible treatment option for Parkinsons Disease
19. Parkinson Disease: Country-Wise Market Analysis
20. Total Market Size of Parkinson Disease for 7 MM (2015-2025)
21. Overview on Total Parkinson Disease Market Geography wise (2016 & 2025)
22. Overview on Total Parkinson Disease Market (2016 & 2025)
22.1. United States Market Size
22.2. Europe Market Size
22.2.1. Germany Market Size
22.2.2. France Market Size
22.2.3. United Kingdom Market Size
22.2.4. Spain Market Size
22.2.5. Italy Market Size
22.3. Japan Market Size
23. Market Drivers
24. Market Restraints
25. Appendix
26. Report Methodology
27. Consulting Services
28. Disclaimer
29. About DelveInsight

List of Table

Table1: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
Table 2: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
Table 3: Diagnosed Cases of Parkinson Disease in France (2015-2025)
Table 4: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
Table 5: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
Table 6: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
Table 7: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
Table 8: Classes of Drugs used for management of Parkinsons Disease
Table 9: List of Marketed Drugs for Parkinson Disease
Table 10: List of Pipeline Phase III Drugs for Parkinson Disease
Table 11: List of Pipeline Phase II Drugs for Parkinson Disease
Table 12: Tozadenant, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: CVT-301, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: Total 7 Major Market Size of Parkinsons disease in USD Million (2015-2025)
Table 17: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 18: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 19: France Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 20: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 21: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 22: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 23: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)

List of Chart

Figure 1: Types of Parkinson Disease
Figure 2: Pathophysiology of Parkinsons Disease
Figure 3: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
Figure 4: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
Figure 5: Diagnosed Cases of Parkinson Disease in France (2015-2025)
Figure 6: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
Figure 7: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
Figure 8: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
Figure 9: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
Figure 10: Treatment Algorithm of Parkinsons Disease
Figure 11: Treatment Algorithm of Parkinsons Disease-continued
Figure 12: Tozadenant, Clinical Trials by Zone (%), 2017
Figure 13: Tozadenant, Clinical Trials by Trial status (%), 2017
Figure 14: CVT-301, Clinical Trials by Zone (%), 2017
Figure 15: CVT-301, Clinical Trials by Trial status (%), 2017
Figure 16: Total 7 Major Market Size of Parkinsons disease in USD Millions (2015-2025)
Figure 17: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2016)
Figure 18: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2025)
Figure 19: Total Market Size of Parkinson Disease in USD Million, (2016)
Figure 20: Total Market Size of Parkinson Disease in USD Million, (2025)
Figure 21: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 22: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 23: France Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 24: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 25: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 26: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 27: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *